Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Candida glabrata Infection: A Case Report

Alina Adee,1,2 Ming D. Ou,1 Efaza Siddiqui,2 Stuart M. Levitz,1 and Richard T. Ellison III1

1Division of Infectious Disease & Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA, and 2Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA

Rezafungin is a semisynthetic, long-acting echinocandin with broad-spectrum activity against many Candida species and Aspergillus species, including a subset of drug-resistant strains. It is currently in phase III trials and was found to be safe and effective for the treatment of candidemia and/or invasive Candida infections in a phase II trial. However, there are no long-term safety or efficacy data. We report on the successful ongoing compassionate use of rezafungin obtained through expanded access for over 1 year in a patient with a multidrug-resistant Candida glabrata mediastinal infection from a vascular graft infection and retained foreign material.

Keywords. antifungal; echinocandin; multidrug-resistant fungal infection; rezafungin.

Invasive fungal infections are a significant cause of mortality and morbidity in humans despite the availability of several antifungal agents [1]. The rise in resistant isolates and species due to selective pressure from use as prophylaxis and treatment in various medical conditions has been particularly problematic, with some isolates being resistant to all currently available antifungals [2]. New antifungal agents have been slow to progress, with only a couple of new agents approved and marketed in the last decade [3]. One of the new antifungals in the pipeline, currently in phase III trials, is rezafungin [4, 5], a novel, long-acting, semisynthetic echinocandin that has broad-spectrum antifungal activity including against subsets of drug-resistant strains [6]. We report on the expanded-access successful use of rezafungin for >1 year for management of a case of recurrent mediastinitis due to a multidrug-resistant Candida glabrata isolate. The patient was initially treated with various antifungal agents with evolution of resistance to azoles and echinocandins, followed by rezafungin with good clinical response and significantly improved tolerability.

CASE REPORT

The patient is a 49-year-old man with no significant medical history, who initially presented to the hospital with a traumatic thoracic aortic tear due to a motor vehicle accident in 2000 requiring emergent thoracic aortic graft repair and splenectomy. In June 2017, he presented to the hospital with fever and chills. Workup revealed thoracic aortic graft infection (Figure 1) and an aorto-bronchial fistula involving the aortic graft; he then underwent resection of the left upper lobe of the lung, explantation of the infected aortic graft, and placement of a new thoracic aortic Dacron graft. Cultures from the explanted graft grew C. albicans, C. glabrata (Isolate 1, Table 1), and Lactobacillus paracasei. The postoperative course was complicated by chylothorax due to disruption of the thoracic duct, which required embolization with multiple platinum-fibered coils. Antimicrobial therapy with intravenous (IV) piperacillin-tazobactam, IV vancomycin, and IV micafungin was completed after 6 weeks, and suppressive therapy with oral fluconazole 800 mg daily was begun, given the concern that the new graft was in a contaminated field.

In October 2019, the patient had recurrent fever and chest pain; a repeat chest computed tomography (CT) scan found increased mediastinal fluid, pneumomediastinum, a potential thrombus in the graft, and a suspected aorto-esophageal fistula. Esophageal endoscopy indicated migration of 1 of the platinum coils from the thoracic duct embolization protruding through the esophageal wall, along with purulent secretions, but no evidence of aorto-esophageal fistula. The coil was removed endoscopically and grew C. glabrata on culture that demonstrated intermediate susceptibility to caspofungin (Isolate 2, Table 1). Antimicrobial therapy including IV micafungin was started and was later changed to IV liposomal amphotericin B after a chest CT scan showed increased gas in the mediastinum as well as narrowing and irregularity of the aortic graft (Figure 2). IV liposomal amphotericin was ultimately changed to oral posaconazole after 6 weeks of therapy.

In February 2020, due to the recurrent mediastinitis while on antifungal therapy with oral posaconazole, the patient underwent a 2-stage procedure with placement of an extra anatomic ascending aorta to supraceliac abdominal aorta bypass graft, followed by excision of the infected thoracic aortic Dacron graft that was originally placed in June 2017. However, the remaining thoracic duct platinum coils were not amenable to safe
extraction and removal. Explanted thoracic graft tissue cultures grew 2 different isolates of *C. glabrata* (Isolates 3, 4, Table 1). The postoperative course was complicated by esophageal perforation requiring a change in antifungal therapy to IV micafungin due to risk of exacerbating esophageal perforation with oral administration. Based on the susceptibility results for both *C. glabrata* isolates—one (Isolate 3) that demonstrated intermediate susceptibility and another (Isolate 4) that demonstrated resistance to micafungin—the antifungal therapy was changed to IV liposomal amphotericin B and oral flucytosine, given with a concurrent 3-week course of antibiotic therapy. Both antifungals were discontinued after 6 weeks of therapy due to renal toxicity.

During outpatient follow-up in April 2020, several long-term suppressive options were discussed due to the retained platinum coils and concern of ongoing chronic infection with multidrug-resistant *C. glabrata*. Antifungal susceptibility testing to rezafungin was performed on an isolate (Isolate 4) from the aortic graft material using the Clinical and Laboratory Standards Institute (CLSI) reference method for broth microdilution antifungal susceptibility testing of yeasts [7]. Sanger sequencing [8] was performed on polymerase chain reaction–amplified “hot spot” (HS) HS1- and HS2-encoding regions of *FKS1* and *FKS2* genes, which showed a D666Y mutation in the *FKS2* gene HS1 [9]. Informed consent and institutional review board approval were obtained through expanded access to starting rezafungin on a compassionate use basis.

IV rezafungin was started in May 2020 with a loading dose of 400 mg, followed by maintenance dosing of 200 mg weekly, which remains ongoing as of this writing. The patient has not exhibited laboratory abnormalities and has only had a transient rash with no evidence of clinical toxicities related to use of rezafungin (Table 2). Serial serum β-D-glucan assays remained negative from May 2020 through June 2021, and a repeat chest CT angiogram in October 2020 did not show any findings suggestive of ongoing infection. A timeline of the patient’s clinical course and antifungal therapy is presented in Figure 3.

### Table 1. Minimum Inhibitory Concentration Values for *Candida glabrata* Isolates for Different Antifungal Agents With Clinical and Laboratory Standards Institute Interpretations

| Drug            | Susceptibility (MIC, µg/mL) and Clinical Interpretation |
|-----------------|---------------------------------------------------------|
|                 | Isolate 1       | Isolate 2       | Isolate 3       | Isolate 4       |
| Caspofungin     | ≤0.25 S         | 0.25 I          | 0.5 R           | 0.5 I           |
| Fluconazole     | 4 S             | 256 R           | >256 R          | 64 R            |
| Voriconazole    | 0.25 NA         | 4 NA            | >8 NA           | NA              |
| Anidulafungin   | 0.12 S          | 0.5 R           | 1 R             | NA              |
| Rezafungin      | NA              | 2 NA            | 0.03 S          | 1 R             |
| Micafungin      | ≤0.06 NA        | ≤0.06 NA        | 0.12 I          | 0.5 R           |
| 5-flucytosine   | ≤0.12 NA        | ≤0.12 NA        | ≤0.12 NA        | NA              |
| Posaconazole    | 1 NA            | >8 NA           | >8 NA           | NA              |
| Itraconazole    | 1 NA            | >16 NA          | >16 NA          | NA              |
| Amphotericin B  | ≤0.12 NA        | 1 NA            | 1 NA            | 0.5 NA          |

Isolate 1: aortic graft explant in 2017; Isolate 2: thoracic duct embolization coil in 2019; Isolate 3: first aortic Dacron graft explant tissue isolate; Isolate 4: second aortic Dacron graft explant tissue isolate in 2020 (48-hour MIC data are reported due to insufficient growth at 24 hours; isolate possesses *FKS2* D666Y mutation).

Abbreviations: I, intermediate; MIC, minimum inhibitory concentration; NA, not applicable; R, resistant; S, susceptible.
DISCUSSION

Treatment of invasive fungal infections remains challenging due to limited options, toxicities, and emergence of resistance in many Candida spp. Multiple novel antifungal agents are in various phases of development including rezafungin, fosmanogepix, and VT-1161 [6]. Recent Food and Drug Administration approval of oral ibrexafungerp for the treatment of vaginal yeast infection is a step forward in expansion of antifungal options [10]. This case report demonstrates the therapeutic challenges encountered while treating a recurrent invasive fungal infection with resistant C. glabrata that necessitated the use of a novel agent due to toxicity with other agents and issues related to the practicability of indefinite use. Our case reports the first known use of rezafungin for an extended duration of >1 year. This patient has demonstrated the safety and tolerability of prolonged use of rezafungin, albeit with the caveat that clinical experience with additional patients is needed. Notably, no significant adverse effects were noted on close serial monitoring, and the patient had a good clinical response with no signs of recurrent infection. However, given the retained platinum coils, clinical cure is not expected and ongoing treatment for an indefinite time is planned.

Rezafungin is a novel intravenous, semisynthetic echinocandin with an extended half-life [11]. It is synthesized from a fermentation product of Aspergillus nidulans. Rezafungin, like other echinocandins, inhibits the 1,3-β-D-glucan synthase enzyme complex, making it intrinsically fungicidal against Candida spp. and fungistatic against Aspergillus spp. It has been

Table 2. Laboratory Results Including Comprehensive Metabolic Panel, Serum B-D-Glucan, and Complete Blood Count Over a Period of 1 Year While on Therapy With Rezafungin

| Test          | 2020 | 2021 |
|---------------|------|------|
|               | May  | June | July | Aug | Sept | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May |
| Sodium, mmol/L| 141  | 141  | 140  | 140 | 140  | 141 | 140 | 140 | 141 | 141 | 140 | 140 | 139 |
| Potassium, mmol/L| 3.7  | 3.7  | 4.5  | 4.1 | 3.9  | 4.1 | 4.3 |    | 4.1 | 3.9 | 3.7 | 4.1 | 3.9 |
| Chloride, mmol/L| 105  | 107  | 106  | 105 | 106  | 107 | 106 | 106 | 107 | 106 | 107 | 106 | 104 |
| CO2, mmol/L    | 28   | 25   | 24   | 26  | 26   | 27  | 26  | 24  | 26  | 26  | 26  | 25  | 25  |
| Glucose, mg/dL | 103  | 85   | 89   | 91  | 93   | 89  | 90  | 108 | 93  | 99  | 109 | 86  | 106 |
| BUN, mg/dL     | 28   | 14   | 17   | 17  | 14   | 18  | 17  | 14  | 21  | 17  | 23  | 19  | 15  |
| Creatinine, mg/dL | 0.91 | 0.90 | 1.03 | 1.07 | 0.83 | 0.92 | 0.90 | 0.90 | 0.89 | 0.90 | 0.86 | 0.93 | 1.05 |
| T. bil, mg/dL  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  | 0.3  |
| ALk phos, U/L  | 129  | 11   | 10   | 13  | 15   | 16  | 15  | 20  | 17  | 15  | 15  | 13  | 20  |
| AST, U/L       | 15   | 11   | 10   | 13  | 15   | 16  | 15  | 20  | 17  | 15  | 15  | 13  | 20  |
| ALT, U/L       | 11   | 9    | 7    | 9   | 11   | 13  | 15  | 16  | 15  | 12  | 14  | 11  | 14  |
| Hemoglobin, g/dL| 10.8 | 10.4 | 10.9 | 11.1 | 11.2 | 11.3 | 11.3 | 12.0 | 11.5 | 11.8 | 12.1 | 12.4 | 13.7 |
| Hematocrit, %  | 33.0 | 32.9 | 34.7 | 34.0 | 34.9 | 35.1 | 36.0 | 38.5 | 35.9 | 37.0 | 37.4 | 38.2 | 41.8 |
| WBC, 10^3/µL   | 6.8  | 6.4  | 6.8  | 5.7  | 6.3  | 6.0  | 7.1  | 6.8  | 6.3  | 7.2  | 9.3  | 7.3  | 5.9  |
| Platelet, 10^3/µL | 274  | 295  | 280  | 273 | 248  | 227 | 235 | 256 | 252 | 290 | 291 | 272 | 212 |
| β-D-glucan     | 49   | 53   | 33   | <31 | <31  | 40  | 56  | 32  | 55  | 52  | 56  | <31 | 39  |

Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; WBC, white blood cell.
shown to deplete the cyst (asci) form of *Pneumocystis* spp. and inhibit the organisms from completing sexual reproduction and proliferation, thereby allowing a broader spectrum of activity against multiple fungal species. As with other echinocandins, rezafungin has poor activity against *Cryptococcus neoformans* and some rare molds, for example, *Mucorales, Fusarium* spp., and *Scedosporium* spp. [12]. The in vitro activity of rezafungin was found to be similar in activity to that of anidulafungin when tested against a collection of clinical isolates of *Candida* spp. enriched with echinocandin- and/or azole-resistant strains. The potency of rezafungin against strains with documented *FKS* mutations was 2- to 8-fold greater than that of caspofungin and similar to that of anidulafungin [13]. The *FKS* genes encode the catalytic subunit of the 1,3-β-D-glucan synthase enzyme complex targeted by echinocandins. Mutations in the *FKS* genes within the 2 specific HS regions (HS1 and HS2, encoding 9 and 8 amino acids, respectively, in *C. glabrata*) are associated with higher minimum inhibitory concentrations (MICs), reduced susceptibility, and increased clinical failure rates [14]. The rezafungin weekly dosing regimen is shown to achieve high plasma concentrations, which might be able to overcome some *FKS* mutations in echinocandin-resistant *Candida* spp. strains [15]. In mouse infection models, rezafungin has demonstrated activity against *C. glabrata* strains possessing *FKS* mutations [16] and has shown a high predicted target attainment for this species [17]. Chronic biofilm studies as well as serial passaging studies show that chronic exposure to rezafungin does not result in the accumulation of *FKS* mutations as with other echinocandins, demonstrating a high barrier to resistance [18].

In a phase 2 double-blind clinical trial, patients with candidemia and/or invasive candidiasis were treated with either once-weekly rezafungin or intravenous caspofungin, with the option for oral fluconazole step-down therapy for up to 4 weeks. Rezafungin was determined to be safe and efficacious [18]. No notable differences were found in treatment-emergent adverse events across different study groups (rezafungin 400 mg/400 mg, rezafungin 400 mg/200 mg, and caspofungin). There was a lower incidence of treatment-emergent adverse events leading to study drug discontinuation and of serious adverse events leading to death in the rezafungin 400 mg/200 mg group [18]. Two phase 3, multicenter, double-blind, randomized clinical trials are currently underway, one to evaluate the efficacy and safety of rezafungin vs the standard antimicrobial regimen to prevent invasive fungal disease in adults undergoing allogeneic hematopoietic stem cell transplant, and the other to evaluate rezafungin vs caspofungin followed by optional oral fluconazole step-down therapy in subjects with candidemia and/or invasive candidiasis [4, 5]. The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product, Fast track, and Orphan Drug designation to rezafungin, but rezafungin has not yet been approved by the FDA for use in humans. In our case, weekly infusions of rezafungin obtained through expanded access were safe and efficacious over an extended period of >1 year.

**Acknowledgments**

The authors would like to acknowledge Cidara Therapeutics for providing rezafungin through their expanded access program and for assistance with susceptibility and genetic testing on 1 of the *C. glabrata* isolates.

**Financial support.** The authors received no financial support for the research, authorship, or publication of this article.

**Potential conflicts of interest.** The authors of this manuscript have no conflicts of interest to disclose. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med 2012; 4:165rv13.
2. Centers for Disease Control and Prevention. Antifungal resistance. Available at: https://www.cdc.gov/fungal/antifungal-resistance.html. Accessed 5 April 2021.
3. Van Dalee R, Spreti I, Walters J, et al. Antifungal drugs: What brings the future? Med Mycol 2019; 57:328–43.
4. Study of rezafungin compared to caspofungin in subjects with candidemia and/or invasive candidiasis (ReSTORE). ClinicalTrials.org identifier: NCT03667690. Updated 18 August 2021. Available at: https://clinicaltrials.gov/ct2/show/NCT03667690. Accessed 5 April 2021.
5. Study of rezafungin compared to standard antimicrobial regimen for prevention of invasive fungal diseases in adults undergoing allogeneic blood and marrow transplantation (ReSPECT). ClinicalTrials.gov identifier: NCT04368559. Updated 19 July 2021. Available at: https://clinicaltrials.gov/ct2/show/NCT04368559. Accessed 5 April 2021.
6. Raio AM, Coler-Reilly A, Larson L, Spec A. Hope on the horizon: novel fungal treatments in development. Open Forum Infect Dis 2020; 7:XXX–XX.
7. CLSI Standard M27. 4th ed. Clinical and Laboratory Standards Institute. 2017.
8. Thompson GR 3rd, Wiederhold NP, Vallor AC, et al. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to *Candida glabrata* infection. Antimicrob Agents Chemother 2008; 52:3783–5.
9. Bordallo-Cardona MA, Escribano P, de la Pedrosa EG, et al. In vitro exposure to increasing micafungin concentrations easily promotes echinocandin resistance in *Candida glabrata* isolates. Antimicrob Agents Chemother 2017; 61:e01542-16.

10. SCYNEXIS. SCYNEXIS announces FDA approval of BREXAFEMME® (ibrexafungerp tablets) as the first and only oral non-azole treatment for vaginal yeast infections. 2 June 2021. Available at: https://d1io3yogibou5.cloudfront.net/_2a4d9ce922e87543a85693ece94d3ba/scynexis/news/2021-06-02_SCYNEXIS_Announces_FDA_Approval_of_BREXAFEMME_240.pdf. Accessed 5 April 2021.

11. Garcia-Effron G. Rezafungin—mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins. *J Fungi (Basel)* 2020; 6:262.

12. Pfaffer MA, Carvalhaes C, Messer SA, Rhomberg PR, Castanheira M. Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY Program, 2016 to 2018). Antimicrob Agents Chemother 2020; 64:e00099-20.

13. Pfaffer MA, Messer SA, Rhomberg PR, et al. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against *Candida* and *Aspergillus* spp., including echinocandin- and azole-resistant isolates. *J Antimicrob Chemother* 2016; 71:2868–73.

14. Perlin DS. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. *Drugs* 2014; 74:1573–85.

15. Lakota EA, Ong V, Flanagan S, Rubino CM. Population pharmacokinetic analyses for rezafungin (CD101) efficacy using phase 1 data. Antimicrob Agents Chemother 2018; 62:e02603-17. Erratum in Antimicrob Agents Chemother 2019; 63:e00333-19.

16. Lepak AJ, Zhao M, VanScoy B, Ambrose PG, Andes DR. Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design. Antimicrob Agents Chemother 2018; 62:e02154-17.

17. Bader JC, Lakota EA, Flanagan S, et al. Overcoming the resistance hurdle: pharmacokinetic-pharmacodynamic target attainment analyses for rezafungin (CD101) against *Candida albicans* and *Candida glabrata*. *Antimicrob Agents Chemother* 2018; 62:e02614-17.

18. Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis—the STRIVE trial. *Clin Infect Dis*. In press.